CRIP1ノックダウンは急性骨髄性白血病における解糖依存性を高め、2-デオキシ-D-グルコースに対する感受性を増強する
Muhammad Asif Zeb1, Faryal Mehwish Awan1, Aamir Ali Khan2
1Department of Medical Lab Technology, The University of Haripur, Haripur, 22620, Khyber Pakhtunkhwa, Pakistan.
Background:
Acute Myeloid Leukemia (AML) is an aggressive hematologic malignancy with suboptimal treatment outcomes, necessitating the development of novel therapeutic strategies. Metabolic reprogramming, particularly a dependency on glycolysis, is a hallmark of cancer cells. The cysteine-rich intestinal protein 1 (CRIP1) gene exhibits dual roles in cancer, but its function in AML metabolism remains unexplored. This study investigated the metabolic consequences of CRIP1 knockdown and the subsequent efficacy of the glycolytic inhibitor 2-deoxy-D-glucose (2-DG) compared to the oxidative phosphorylation (OXPHOS) inhibitor IACS-010759.
Methods:
Stable CRIP1 knockdown (CRIP1-KD) was established in the OCI-AML3 cell line using lentiviral shRNA. Metabolic changes were assessed by measuring glucose consumption and lactate secretion. Expression of lactate dehydrogenase A (LDHA) was evaluated by Western blot. The cytotoxic effects of 2-DG and IACS-010759 were determined via flow cytometry using 7-AAD staining.
Results:
CRIP1-KD cells demonstrated an 87% reduction in CRIP1 expression (*p*<0.001) and a significant increase in both glucose uptake (*p*=0.04) and lactate production (*p*=0.01) compared to scramble control (SCR) cells. This glycolytic phenotype was corroborated by a 3.3-fold upregulation in LDHA protein expression. Treatment with 2-DG resulted in a more pronounced suppression of glucose consumption and lactate production than IACS-010759 in CRIP1-KD cells (*p*=0.01). Consequently, CRIP1-KD cells exhibited significantly higher cell death after 2-DG treatment (29.10%) compared to IACS-010759 treatment (17.25%; *p*=0.003).
Conclusion:
Our findings indicate that CRIP1 knockdown induces a glycolytic switch in AML cells, rendering them exquisitely sensitive to glycolytic inhibition by 2-DG. This suggests that CRIP1 status could serve as a biomarker for predicting response to metabolic therapies and highlights 2-DG as a promising therapeutic agent for a subset of AML characterized by glycolytic dependency.
関連する概念動画
Other Glycolytic Pathways
Self-Evaluation: Self-Enhancement and Self-Verification
Increasing Function
Glucose Homeostasis: Regulation of Blood Glucose
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
Frequency-dependent Selection
Temperature Dependence on Reaction Rate
Atoms, molecules, or ions must collide before they can react with each other. Atoms must be close together to form chemical bonds. This premise is the basis for a theory that explains many observations regarding chemical kinetics, including factors affecting reaction rates.
The collision theory is based on the postulates that (i) the reaction rate is proportional to the rate of reactant collisions, (ii) the reacting species collide in an orientation allowing contact between...


